Tetracycline to Prevent Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rashes: Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N03CB)(1)

PURPOSE: Epidermal growth factor receptor inhibitors are effective cancer therapies, but they cause a rash in greater than 50% of patients. This study tested tetracycline for rash prevention. METHODS: This placebo-controlled, double-blinded trial enrolled patients who were starting cancer treatment...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jatoi, Aminah, Rowland, Kendrith, Sloan, Jeff A., Gross, Howard M., Fishkin, Paul A., Kahanic, Stephen P., Novotny, Paul J., Schaefer, Paul L., Johnson, David B., Tschetter, Loren K., Loprinzi, Charles L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3918166/
https://ncbi.nlm.nih.gov/pubmed/18543329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23621
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados